^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Zejula (niraparib) (PARP inhibitor) + tuvusertib (M1774) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
6210 / 12 - Combination of M1774 and niraparib can overcome ATR and PARP inhibitor resistance in BRCA1 mutated ovarian cancer models
Published date:
03/15/2023
Excerpt:
Collectively, these results indicate that the combination of M1774 and niraparib can overcome PARP inhibitor resistance and ATR inhibitor resistance in BRCA1-mutant ovarian cancer PDX models and demonstrate the utility of organoid cultures for discerning mechanisms of resistance and strategies to restore drug sensitivity.
